Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

THR-687 - Further readings

A novel integrin alpha5beta1 binding domain in module 4 of connective tissue growth factor (CCN2/CTGF) promotes adhesion and migration of activated pancreatic stellate cells.
Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761.
Angiopoietin 2 induces astrocyte apoptosis via alphavbeta5-integrin signaling in diabetic retinopathy.
Angiopoietin 2 induces pericyte apoptosis via alpha3beta1 integrin signaling in diabetic retinopathy.
Angiopoietin-2 stimulation of endothelial cells induces alphavbeta3 integrin internalization and degradation.
Association between diabetic retinopathy and genetic variations in alpha2beta1 integrin, a platelet receptor for collagen.
Definition of two angiogenic pathways by distinct alpha v integrins.
Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR).
Expression of advanced glycation end products and related molecules in diabetic fibrovascular epiretinal membranes.
Expression of integrins in human proliferative diabetic retinopathy membranes.
Immunolocalization of integrins in proliferative retinal membranes.
Inhibition of experimental choroidal neovascularization in rats by an alpha(v)-integrin antagonist.
Integrin activation is required for VEGF and FGF receptor protein presence on human microvascular endothelial cells.
Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity.
Integrins in angiogenesis and lymphangiogenesis.
Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis.
N-acetylglucosaminyltransferase V negatively regulates integrin alpha5beta1-mediated monocyte adhesion and transmigration through vascular endothelium.
Ocular Distribution and Pharmacodynamics of SF0166, a Topically Administered alphavbeta3 Integrin Antagonist, for the Treatment of Retinal Diseases.
Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent.
Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization.

Pages